Direct oral anticoagulants (DOACs) are increasingly used for prevention and treatment of venous thromboembolism and for prevention of stroke in patients with non-valvular atrial fibrillation.

Anticoagulant reversal should only be considered with life-threatening bleeds, with bleeds that fail to respond to usual measures, and in patients requiring urgent surgery.

Idarucizumab is licensed for dabigatran reversal. The Factor Xa inhibitor andexanet alfa has recently been licensed in the US for reversal of rivaroxaban, apixaban and edoxaban.

Related Articles


Article icon
Management of Complications in Anticoagulated Patients with Atrial…

George D Katritsis, Demosthenes G Katritsis,

Citation: Arrhythmia & Electrophysiology Review 2017;6(4):167–78.

Anticoagulation in Atrial Fibrillation – Current Concepts

Demosthenes G Katritsis, Bernard J Gersh, A John Camm,

Citation: Arrhythmia & Electrophysiology Review 2015;4(2):100–7

NOACs: Monitoring their Anticoagulant Effects and Use of Antidotes

Nur A Rahmat, Gregory YH Lip,

Citation: Arrhythmia & Electrophysiology Review 2015;4(1):90–5

Dental Procedures in Patients with Atrial Fibrillation and New Oral…

Pepie Tsolka,

Citation: Arrhythmia & Electrophysiology Review 2014;3(2):85–9